“pd-1” Archives

in
Entry Author Date Location
FDA’s Latest Cancer Approval Underscores Immunotherapy Nobel Prize 10/01/18 National
Nobel Medicine Prize Honors Cancer Immunotherapy Pioneers Allison, Honjo 10/01/18 National
IDO Don’ts: After Immunotherapy Failure, Experts Say Slow Down 05/31/18 National
Bio Roundup: CBO’s Praise, Celgene’s Shock, Trump’s Opioid Plan & More 10/27/17 National
On ASCO’s Eve, Experts Fret Over Backlash to Cancer Combo Frenzy 05/30/17 National
With $55M, Neon Wants To Make the Cancer Vaccine “Problem” Personal 10/01/15 Boston
New CEO and $80M Later, Syndax Looks Prepped for Second IPO Try 08/24/15 Boston
Sanofi, Regeneron Set Sights on Immuno-Oncology With New $2B+ Pact 07/28/15 New York
Crossovers Arm Jounce With $56M For “Next Step” Immuno-Oncology 04/23/15 Boston
Pivoting From IPO, Syndax Inks Combo Trial Deal With Merck 03/31/15 Boston
East Coast Biotech Roundup: Varmus, Bristol, Aerie, Aura & More 03/06/15 Boston
Yes to Flexus: The Science And Strategy Behind A Huge Biotech Return 02/26/15 San Francisco
Syndax CEO Says an Immuno-Oncology Thing Happened on the Way to IPO 02/17/15 Boston
East Coast Biotech Roundup: Foundation, Biogen, Moderna, & Lots More 01/16/15 Boston
ASH Roundup: Immunotherapy Stars, Gene Therapy Leaps Ahead 12/11/14 San Francisco
East Coast Biotech Roundup: Agios, Vertex, Epizyme, Celldex, & More 11/21/14 Boston
What Early Looks From ASH Tell Us About Cancer Immunotherapy 11/07/14 National
East Coast Biotech Roundup: Sarepta, Aegerion, Syros, Aileron & More 10/31/14 Boston
Try Then Buy? Sutro Deal Could Be Celgene’s Biggest Antibody Bet Yet 10/23/14 New York
East Coast Biotech Roundup: Raze, Retrophin, Alnylam, & More 10/16/14 Boston
East Coast Biotech Roundup: Infinity, Merck, Voyager, Ebola, & More 09/05/14 Boston
Merck, Leapfrogging Bristol-Myers, Wins FDA Nod for Cancer Drug 09/04/14 New York
Enumeral Raises $21.5M, Heads to the OTC Via Reverse Merger 08/04/14 Boston
East Coast Biotech Roundup: Regeneron, Sarepta, Jounce, & More 07/11/14 Boston
New Jounce CEO Aims to Place the Right Immuno-Oncology Bets 07/11/14 Boston
Celldex, Bristol-Myers Cut Deal on Immuno-Oncology Combo Trial 05/14/14 New York
Five Prime, Bristol-Myers Squibb Cut $350M Immuno-Oncology Deal 03/17/14 San Francisco
East Coast Biotech Roundup: ImmusanT, NY Disruptors, Tesaro, & More 03/14/14 Boston
Partnership with AnaptysBio Gives Tesaro Entrée to Immuno-Oncology 03/13/14 San Diego
East Coast Biotech Roundup: VentriNova, RainDance, Biogen, & More 03/07/14 Boston
Page 1 of 2 next page »